What is Vista Pharmaceuticals Ltd (524711) share price return in the past 10 years?

Vista Pharmaceuticals Ltd share price has declined -5.4% annually (CAGR) over the past ten years.

What is the share price of Vista Pharmaceuticals Ltd (524711)?

Company share prices are keep on changing according to the market conditions. The current trading price of Vista Pharmaceuticals Ltd (524711) on 04-Jun-2026 16:59:59 at 16:59 is 7.72.

What is the P/E ratio of Vista Pharmaceuticals?

The latest standalone P/E ratio of Vista Pharmaceuticals as of 04-Jun-2026 is 0.00.

What is the P/B ratio of Vista Pharmaceuticals Ltd (524711)?

The latest standalone P/B ratio of Vista Pharmaceuticals Ltd (524711) as of 04-Jun-2026 is 1.30.

What is the 52-week high and low of Vista Pharmaceuticals Ltd (524711)?

The 52-week high of Vista Pharmaceuticals Ltd (524711) is Rs. 12.01 and the 52-week low is Rs. 5.71.

Vista Pharmaceuticals Ltd (524711) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Vista Pharmaceuticals Ltd (524711)
Brand: Vista Pharmaceuticals

Vista Pharmaceuticals Ltd (524711)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524711 NSE: Pharmaceuticals & Drugs | Small Cap | Vista Pharma Share Price

Vista Pharmaceuticals Ltd (524711)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524711 NSE: Pharmaceuticals & Drugs | Small Cap | Vista Pharma Share Price

Key Metrics

Valuation Multiples

Market Cap

₹48 Cr.

Current Price

₹7.7

52-Week Low / High

₹6 / 12

TTM EPS

₹-2

TTM Sales

₹5.4 Cr.

Book Value per Share

₹5.9

P/E Ratio

0.00

Industry PE

46.5

Price to Book (P/B)

1.30

In line with its 5-year historical median

Price to Sales (P/S)

8.80

In line with its 5-year historical median

EV/EBITDA

-4.01

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

-11.47%

Underperforms industry median

Return on Capital Employed (ROCE)

-8.54%

Underperforms industry median

Return on Assets (ROA)

-8.41%

Operating Profit Margin

-38.6%

Net Profit Margin

-46.14%

Gross Profit Margin

-45.2%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-2.14%

Operating Profit Growth (1 Year)

Net Profit Growth (1 Year)

Asset Quality

Promoter Holding

21.19%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹24 Cr.

Equity

₹12.3 Cr.

Face Value

₹2

All Time Low / High

₹0.08 / 56.15

Vista Pharmaceuticals stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Vista Pharmaceuticals Ltd a good quality company?

Vista Pharmaceuticals Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Vista Pharmaceuticals Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Vista Pharmaceuticals Ltd vs industry peers?

Vista Pharmaceuticals Ltd revenue CAGR is -15.05%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Vista Pharmaceuticals Ltd?

Promoters hold 21.19% of the Vista Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Vista Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -7% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	9.6%	8.9%	12.4%	6.3%	-5.2%	-5.1%	-3.8%	-9.6%	-8.3%	-8.5%	-
Value Creation Index ⓘ	-0.3	-0.4	-0.1	-0.6	-1.4	-1.4	-1.3	-1.7	-1.6	-1.6	-
Growth Parameters ⓘ
Sales ⓘ	15.4	24.2	28.9	31.1	22.8	1.3	0.4	1	10.3	10.1	5
Sales YoY Gr.	-	57.2%	19.6%	7.4%	-26.8%	-94.4%	-69.3%	156.4%	929%	-2.1%	-
Adj EPS ⓘ	0.4	0.5	0.7	0	-1.3	-0.6	-0.2	-1.5	-1	-0.8	-2
YoY Gr.	-	34.3%	48.9%	-100%	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	4.5	6.3	9	11	9.8	8.9	9.6	8.1	7.6	7.4	5.9
Adj Net Profit ⓘ	0.9	1.3	2	0	-3.8	-2	-0.9	-5.6	-4.5	-4.6	-12
Cash Flow from Ops. ⓘ	-2.5	2.6	-4.6	3.3	0.8	-6.8	-1	-1.7	-4.9	-7	-
Debt/CF from Ops. ⓘ	-3.2	4.4	-2.4	3.4	19.3	-1.6	-12.6	-5.8	-1.6	-1.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-4.6%	-15.1%	195.6%	-2.1%
Adj EPS ⓘ	-208.8%	NA	NA	NA
BVPSⓘ	5.7%	-5.4%	-8.5%	-2.4%
Share Price	-5.4%	-7.2%	-5.8%	-29.5%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	8	9	8.4	0	-11.6	-6.4	-2.5	-15.4	-11.6	-10.8	-29.5
Op. Profit Mgn % ⓘ	17.7	12.6	18.5	4	-21.1	-136.6	-306.8	-386.9	-33.4	-38.6	-139.9
Net Profit Mgn % ⓘ	5.6	5.2	7	0	-16.6	-158.6	-215.1	-552.7	-43.4	-45.9	-223.4
Debt to Equity ⓘ	0.7	0.7	0.4	0.3	0.5	0.3	0.4	0.3	0.2	0.2	0.1
Working Cap Days ⓘ	332	270	290	287	351	6,408	21,738	8,671	878	937	243
Cash Conv. Cycle ⓘ	95	52	59	153	249	3,977	13,580	6,495	313	213	28

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	15.38	24.18	28.92	31.07	22.76	1.27	0.39	1	10.29	10.07
Operating Expenses ⓘ +	12.78	21.13	23.58	29.84	27.56	3	1.66	5.32	13.84	14.10
Manufacturing Costs	1.18	0.93	1.63	0.84	1.85	0.42	0.29	0.38	1.05	1.03
Material Costs	9.57	16.10	15.96	25.41	22.97	0.73	0.37	2.83	8.89	8.35
Employee Cost	0.81	0.70	0.87	1.18	1.31	1.15	0.57	0.51	1.79	2
Other Costs ⓘ	1.22	3.40	5.11	2.40	1.43	0.69	0.43	1.60	2.10	2.72
Operating Profit ⓘ	2.60	3.06	5.34	1.24	-4.80	-1.73	-1.27	-4.32	-3.55	-4.03
Operating Profit Margin (%)	16.9%	12.6%	18.5%	4.0%	-21.1%	-136.0%	-321.0%	-430.0%	-34.5%	-40.0%
Other Income ⓘ +	0.02	0.06	0.40	2.95	3.75	0.20	0.17	0.40	0.33	0.44
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.77	0.88	1.57	1.67	1.54	1.55	0.90	1.34	1.24	0.97
Depreciation ⓘ	1.02	1.02	1.34	1.36	1.35	0.73	0.62	0.62	0.72	0.74
Profit Before Tax ⓘ	0.84	1.22	2.83	1.15	-3.94	-3.81	-2.62	-5.88	-5.18	-5.29
Tax ⓘ	0.06	-0.02	0.64	0.21	-0.26	-1.80	-1.73	-0.21	-0.67	-0.64
Profit After Tax	0.77	1.25	2.19	0.94	-3.68	-2.01	-0.89	-5.66	-4.51	-4.65
PAT Margin (%)	5.0%	5.2%	7.6%	3.0%	-16.2%	-158.0%	-225.0%	-564.0%	-43.9%	-46.1%
Adjusted EPS (₹)	0.3	0.5	0.8	0.3	-1.2	-0.6	-0.2	-1.5	-1.0	-0.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Vista Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	11.21	16.61	26.29	33.32	29.64	32.84	35.45	30.55	35.65	45.41
Share Capital ⓘ	5	5.31	5.83	6.07	6.07	7.36	7.36	7.51	9.43	12.31
Reserves ⓘ	6.21	11.29	20.46	27.25	23.57	25.49	28.09	23.04	26.22	33.10
Debt +	7.88	11.33	11.06	11.17	15.47	10.71	12.55	9.96	7.96	7.40
Long Term Debt	7.88	6.03	5.88	5.96	5.51	8.69	7.43	5.18	2.93	2.38
Short Term Debt	0	5.30	5.18	5.21	9.96	2.02	5.13	4.78	5.03	5.02
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	6.55	12.93	9.13	5.25	5.16	5.11	5.37	7.80	7.41	5.59
Others Liabilities ⓘ	0.74	0.15	6.23	2.90	0.47	3.94	-1.26	5.07	3.65	-2.49
Total Liabilities ⓘ	26.38	41.03	52.71	52.64	50.74	52.61	52.11	53.39	54.67	55.92
Fixed Assets
Net Fixed Assets ⓘ +	9.96	13.46	17.67	20.52	20.66	19.93	19.33	19.74	19.32	18.70
Gross Block	18.74	14.47	20.02	24.24	25.72	25.72	25.74	26.76	27.06	27.18
Accumulated Depreciation	8.78	1.02	2.35	3.71	5.06	5.79	6.41	7.02	7.74	8.48
CWIP ⓘ	0	1.99	7.11	8.54	8.78	9.08	9.08	9.33	9.82	10.14
Investments ⓘ	0	0	0.02	0.03	0.02	0.04	0.03	0.02	0.02	0.05
Inventories	2.68	8.14	10.91	11.25	9.68	9.68	9.33	7.68	6.79	8.22
Trade Receivables	9.74	9.01	10.86	8.35	10.28	2.17	10.46	11.25	4.19	3.39
Cash Equivalents	0.43	5.77	1.79	0.87	0.23	0.14	0.07	0.20	0.09	0.73
Others Assets ⓘ	3.57	2.65	4.36	3.08	1.09	11.56	3.80	5.17	14.44	14.69
Total Assets ⓘ	26.38	41.03	52.71	52.64	50.74	52.61	52.11	53.39	54.67	55.92

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-2.50	2.57	-4.58	3.30	0.80	-6.75	-0.99	-1.71	-4.91	-6.98
PBT ⓘ	0.84	1.22	2.83	1.15	-3.94	-3.69	-2.62	-5.88	-5.18	-5.29
Adjustment ⓘ	1.78	1.88	2.61	2.03	1.91	2.25	1.51	1.83	1.94	1.73
Changes in Working Capital ⓘ	-4.93	-0.52	-10.03	0.5	2.83	-5.31	0.12	1.28	-1.68	-3
Tax Paid ⓘ	-0.18	0	0	-0.38	0	0	0	1.05	0	-0.43
Cash Flow From Investing Activity ⓘ +	-0.24	-3.61	-10.61	-5.65	-1.73	-0.30	-0.01	-1.27	-0.79	-0.44
Capex	-0.25	-3.64	-10.66	-5.65	-1.73	-0.30	-0.01	-1.27	-0.79	-0.44
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.01	0.03	0.05	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	3.07	6.36	11.22	1.43	0.28	6.96	0.94	3.11	5.59	8.06
Net Proceeds from Shares ⓘ	0	3.78	7.49	0.24	0	9	0	0.76	9.61	14.39
Net Proceeds from Borrowing ⓘ	7.88	6.03	-0.15	0.07	-0.45	3.19	0.67	-2.25	-2.25	-0.55
Interest Paid ⓘ	-0.77	-0.88	-1.57	-1.67	-1.54	-1.55	-0.90	-1.21	-1.22	-0.96
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-4.04	-2.57	5.45	2.79	2.27	-3.68	1.16	5.81	-0.55	-4.81
Net Cash Flow ⓘ	0.34	5.32	-3.98	-0.92	-0.64	-0.09	-0.07	0.13	-0.11	0.64

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	7.15	8.97	10.19	3.15	-11.68	-6.43	-2.6	-17.16	-13.63	-11.47
ROCE (%)	9.57	8.92	12.42	6.28	-5.2	-5.1	-3.75	-9.58	-8.28	-8.54
Asset Turnover Ratio	0.63	0.72	0.62	0.59	0.44	0.02	0.01	0.02	0.19	0.18
PAT to CFO Conversion(x)	-3.25	2.06	-2.09	3.51	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	249.70	141.60	125.40	112.80	149.40	1,794.10	5,842.80	3,948.40	273.90	137.30
Inventory Days	34.40	81.70	120.30	130.10	167.80	2,790.40	8,791.50	3,091.80	256.60	271.80
Payable Days	272.70	220.80	252.20	103.30	82.70	2,566.30	5,213	849.70	312.20	284.30

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vista Pharmaceuticals Ltd FAQs

The current trading price of Vista Pharma on 04-Jun-2026 16:59 is ₹7.72.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Vista Pharma stood at ₹47.52 Cr

The latest P/E ratio of Vista Pharma as of 03-Jun-2026 is 0.00.

The latest P/B ratio of Vista Pharma as of 03-Jun-2026 is 1.30.

The 52-week high of Vista Pharma is ₹12.01 and the 52-week low is ₹5.71.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vista Pharma is ₹5.40 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Vista Pharmaceuticals Ltd is a below average quality company.

The key valuation ratios of Vista Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vista Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Limited was incorporated on January 25,1991 under the Companies Act of 1956 with the Registrar of Companies Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991. Vista Pharmaceuticals was incorporated by Dr. Dhananjaya Alli & his associates. The capital was subscribed by Vista Pharmaceuticals Inc., an Overseas Corporate Body promoted by them as a per the laws of State of New Jersy, United States of America.

The Company was in process of setting up a 100% EOU for manufcacture of drug formulations with an installed capacity of 400 million tablets & 200 million capsules per annum.

Vista, the largest division of Torrent Pharmaceuticals Ltd, offers a range of products mainly in the therapeutic areas of gastrointestinal, pain management and anti-infective, catering to common ailments. This division is a primary contributor to the domestic sales of Torrent Pharmaceuticals Ltd.

Vista Pharmaceuticals Ltd (524711)

Vista Pharmaceuticals Ltd (524711)

Vista Pharmaceuticals stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Vista Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vista Pharmaceuticals Ltd FAQs

About Vista Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Vista Pharmaceuticals Ltd (524711)

Vista Pharmaceuticals Ltd (524711)

Vista Pharmaceuticals stock performance

Check Before You Invest

M-Cap below 100cr DeciZen not available

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Vista Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vista Pharmaceuticals Ltd FAQs

What is the share price of Vista Pharma?

What is the market cap of Vista Pharma?

What is the P/E ratio of Vista Pharma?

What is the P/B ratio of Vista Pharma?

What is the 52-week high and low of Vista Pharma?

What is the TTM revenue of Vista Pharma?

Is Vista Pharmaceuticals Ltd a good quality company?

Is Vista Pharmaceuticals Ltd undervalued or overvalued?

Is Vista Pharmaceuticals Ltd a good buy now?

About Vista Pharmaceuticals Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.